Biotech Companies Report Q1 Results: Neuronetics Beats Consensus, Voyager Therapeutics Surpasses Expectations, Y-mAbs Therapeutics Outperforms Estimates
- May 09th, 2023
- 569 views
Neuronetics, Inc. (Nasdaq: STIM) has reported a Q1 loss of $0.38 per share, which was slightly better than the consensus loss of $0.39 per share. As of this writing, $STIM is trading at $2.89, up by 31.36% or $0.69.
Meanwhile, Voyager Therapeutics, Inc. (Nasdaq: VYGR) has reported Q1 EPS of $2.94, which exceeded the consensus estimate of $0.77. This positive news has resulted in a surge in the company's stock price, with $VYGR trading at $10.36, up by 24.67% or $2.05.
In other news, Y-mAbs Therapeutics, Inc. (Nasdaq: YMAB) has reported a Q1 loss of $0.15 per share, which was better than the consensus loss of $0.32 per share. This has resulted in a positive trend for the company's stock price, with $YMAB trading at $8.55, up by 26.29% or $1.78.
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)
Post Your Comments
Want To Find Some News?
Recent Posts
-
DOT, DoW, DHS Join Forces to Protect Southern Border Airspace
October 16th, 2026FTC Sues Ticket Broker Over Unlawful Tactics Used to Buy Millions of Tickets to Popular Live Events
October 15th, 2026October 15th, 2026FDA Approves First Treatment for Certain People With BCG-Unresponsive Bladder Cancer
October 14th, 2026U.S. Treasury Announces Record Enforcement Actions Against Bank of America
October 14th, 2026
Member Login